Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE) $2.37 -0.17 (-6.69%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$2.35▼$2.5550-Day Range$1.65▼$2.6552-Week Range$1.63▼$20.73Volume1.18 million shsAverage Volume2.64 million shsMarket Capitalization$233.68 millionP/E RatioN/ADividend YieldN/APrice Target$10.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.15 Rating ScoreUpside/Downside340.4% Upside$10.44 Price TargetShort InterestBearish12.52% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.79) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector293rd out of 948 stocksBiological Products, Except Diagnostic Industry45th out of 147 stocks 4.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.44, Fate Therapeutics has a forecasted upside of 340.4% from its current price of $2.37.Amount of Analyst CoverageFate Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.52% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 1.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.04% of the stock of Fate Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.79) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fate Therapeutics Stock (NASDAQ:FATE)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesNovember 12, 2023 | seekingalpha.comFate Therapeutics: Getting There, But PerpetuallyNovember 12, 2023 | morningstar.comFate Therapeutics Inc FATEDecember 6, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. November 10, 2023 | markets.businessinsider.comFate Therapeutics: Promising Developments and Buy Rating Justified by Clinical Trials and Financial StandingNovember 9, 2023 | markets.businessinsider.comTD Cowen Keeps Their Hold Rating on Fate Therapeutics (FATE)November 9, 2023 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | msn.comFate Therapeutics files $300M mixed securities shelfNovember 9, 2023 | finance.yahoo.comFATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/YDecember 6, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. November 9, 2023 | finanznachrichten.deFate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 8, 2023 | msn.comFate Therapeutics GAAP EPS of -$0.46 beats by $0.12, revenue of $1.94M beats by $1.04MNovember 8, 2023 | finance.yahoo.comFate Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 8, 2023 | finance.yahoo.comFate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business UpdatesOctober 25, 2023 | finance.yahoo.comFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial ResultsOctober 2, 2023 | marketwatch.comAura Biosciences Names Hopkins as Chief Medical OfficerSeptember 29, 2023 | markets.businessinsider.comBuy Rating Assigned to Fate Therapeutics: An Analysis of the Ono Program and Recent SITC UpdatesSeptember 7, 2023 | msn.comCantor Fitzgerald Reiterates Fate Therapeutics (FATE) Neutral RecommendationAugust 31, 2023 | finance.yahoo.comFate Therapeutics to Present at Upcoming September Investor ConferencesAugust 17, 2023 | msn.comTruist Securities Reiterates Fate Therapeutics (FATE) Hold RecommendationAugust 16, 2023 | msn.comFate Therapeutics: Not Now, Maybe Never?August 16, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Fate TherapeuticsAugust 11, 2023 | msn.comMorgan Stanley Maintains Fate Therapeutics (FATE) Equal-Weight RecommendationAugust 10, 2023 | msn.comEF Hutton Reiterates Fate Therapeutics (FATE) Buy RecommendationAugust 10, 2023 | msn.comBMO Capital Maintains Fate Therapeutics (FATE) Market Perform RecommendationAugust 9, 2023 | finance.yahoo.comFATE Q2 Earnings Beat on Lower Expenses, Revenues MissAugust 8, 2023 | finance.yahoo.comFate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comFate Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesSee More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees551Year FoundedN/APrice Target and Rating Average Stock Price Target$10.44 High Stock Price Target$65.00 Low Stock Price Target$3.00 Potential Upside/Downside+340.4%Consensus RatingHold Rating Score (0-4)2.15 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($1.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,720,000.00 Net Margins-163.04% Pretax Margin-163.04% Return on Equity-38.44% Return on Assets-28.11% Debt Debt-to-Equity RatioN/A Current Ratio8.81 Quick Ratio8.81 Sales & Book Value Annual Sales$96.30 million Price / Sales2.43 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book0.48Miscellaneous Outstanding Shares98,600,000Free Float93,632,000Market Cap$233.68 million OptionableOptionable Beta1.57 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 53)Founder, CEO, President & Director Comp: $645kMr. Edward J. Dulac III (Age 47)Chief Financial Officer Comp: $455kMs. Cindy R. Tahl (Age 50)General Counsel & Corporate Secretary Comp: $455kDr. Bahram Valamehr Ph.D. (Age 46)Chief Research & Development Officer Comp: $455kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityMore ExecutivesKey CompetitorsAlloVirNASDAQ:ALVRCompass TherapeuticsNASDAQ:CMPXFennec PharmaceuticalsNASDAQ:FENCInnate PharmaNASDAQ:IPHASOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 15,848 shares on 11/30/2023Ownership: 0.038%Deutsche Bank AGSold 200,711 shares on 11/24/2023Ownership: 0.045%Graham Capital Management L.P.Sold 120,711 shares on 11/22/2023Ownership: 0.022%Walleye Capital LLCSold 286,567 shares on 11/21/2023Ownership: 0.103%Diversified Trust CoSold 11,357 shares on 11/17/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions FATE Stock Analysis - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price target for 2024? 20 brokerages have issued 12-month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $3.00 to $65.00. On average, they anticipate the company's share price to reach $10.44 in the next twelve months. This suggests a possible upside of 340.4% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2023? Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 76.5% and is now trading at $2.37. View the best growth stocks for 2023 here. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.13. The biopharmaceutical company earned $1.94 million during the quarter, compared to the consensus estimate of $0.99 million. Fate Therapeutics had a negative net margin of 163.04% and a negative trailing twelve-month return on equity of 38.44%. What ETF holds Fate Therapeutics' stock ? iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.49%), Jacobs Levy Equity Management Inc. (2.42%), Acadian Asset Management LLC (2.18%), Monaco Asset Management SAM (1.87%), Charles Schwab Investment Management Inc. (0.90%) and Healthcare of Ontario Pension Plan Trust Fund (0.45%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:FATE) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.